2021/2/9@WHO@The COVID-19 candidate vaccine landscape

@

Route ’Žห•๛–@

IM: intramuscular  ‹ุ“๗’Žห
SC:
subcutaneous injection  ”็‰บ’Žห
ID:
intradermal injection   ”็“เ’Žห
IV: 
intraveneous   ร–ฌ“เ’Žห

@

Developer/manufacturer Platform Type doses Timing
@
days
Route Phase ณ”F
# EUA
@
AstraZeneca + University of Oxford Non-Replicating Viral Vector ChAdOx1-S- (AZD1222) (Covishield) 1-2 0, 28  IM ‡V

UK  2020/12/30
EU   2021/1/29
WHO 2021/2/15
“๚–{ 2021/5/21

@
CanSino Biological Inc./Beijing Institute of Biotechnology Non-Replicating Viral Vector Adenovirus Type 5 Vector 1 @ IM ‡V

’†‘ 2021/2/26

—LŒ๘ซ  65.28%
5/18 ฺŽํŠJŽn

Gamaleya Research Institute ; Health Ministry of the Russian Federation Non-Replicating Viral Vector Gam-COVID-Vac  Adeno-based (rAd26-S+rAd5-S) 2 0, 21 IM ‡V@

Sputnik V
ƒƒVƒA@2020/8

@
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"@@@(Russia) Protein Subunit EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) 2 0, 21 IM ‡T/‡U

EpiVacCorona
ƒƒVƒA@2020/10

@
Janssen Pharmaceutical (Johnson & Johnson) Non-Replicating Viral Vector Ad26COVS1 1 @ IM ‡V

FDA 2021/2/27#
WHO 2021/3/12

2021/5/24“๚–{\ฟ
Sinovac Research and Development Inactivated Inactivated 2 0, 14 IM ‡V

’†‘ 2021/2/6
WHO 2021/6/1


’†‘2Œ–ฺ

Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products  Inactivated Inactivated 2 0, 21 IM ‡V

’†‘ 2021/2/26

—LŒ๘ซ  72.51%

Sinopharm  + China National Biotec Group Co + Beijing Institute of Biological Products Inactivated Inactivated(Vero cell) 2 0, 21 IM ‡V@

’†‘ 2020/12/31
WHO 2021/5/7

@
Bharat Biotech International (ƒCƒ“ƒhj Inactivated Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) 2 0, 14 IM ‡V@

Covaxin
ƒCƒ“ƒh 2021/1/3

@
Moderna/NIAIDi•ฤ‘—งƒAƒŒƒ‹ƒM[Šด๕วŒค‹†Šj RNA mRNA -1273 2 0, 28 IM ‡V

FDA 2020/12/17
                  EUA
EU 2021/1/6
“๚–{ 2021/5/21

FDA 12`17@ณ”F‰„Š๚

 Pfizer/BioNTech 
+ Fosun Pharma 
iใŠC•œฏˆใ–๒j
RNA BNT162 (3 LNP-mRNAs )

ป•i–ผFCOMIRNATY

2 0, 28 IM ‡V

UK 2020/12/2
FDA 2020/12/11
                 EUA
FDA 2021/8/23@
EU 2020/12/21
WHO 2020/12/31
“๚–{ 2021/2/14

FDA 2021/5/10
  12`15ฮ‚เ

FDAณŽฎณ”F‚อ16ฮˆศใ

Novavaxi•ฤj Protein Subunit SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) 2 0, 21 IM ‡V @ @
University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy Replicating Viral Vector DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) 1 @ IN ‡U @ @
Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Protein Subunit Recombinant SARS-CoV-2 vaccine (CHO Cell)  2 or
3
0, 28
0, 28, 56
IM ‡V@ @ @
CureVac AGi“ฦj RNA CVnCoV Vaccine 2 0, 28 IM ‡V @ @
Institute of Medical Biology + Chinese Academy of Medical Sciences Inactivated SARS-CoV-2 vaccine (vero cells 2 0, 28 IM ‡V@ @ @
Research Institute fo Bological Safety Problems, Rep. of Kazakhstan Inactivated QazCovid-in® - COVID-19 inactivated vaccine 2 0, 21 IM ‡V @ @
Beijing Minhai Biotechnology Inactivated Inactivated SARS-CoV-2 vaccine (Vero cell)  1,2 or 3 @ IM ‡U @ @
Inovio Pharmaceuticals (•ฤj+ International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd  DNA INO-4800+electroporation  2 0, 28 ID ‡U/‡V @ @
Osaka University/ AnGes/ Takara Bio DNA AG0301-COVID19 2 0, 14 IM ‡U/‡V @ @
Zydus Cadila(ƒCƒ“ƒhj DNA nCov vaccine 3 0, 28, 56 ID ‡V @ @
Genexine Consortium (Šุ‘j DNA DNA Vaccine (GX-19) 2 0, 28 IM ‡T/‡U @ @
Kentucky Bioprocessingi•ฤj Protein Subunit KBP-COVID-19 (RBD-based) 2 0, 21  IM ‡T/‡U @ @
Sanofi Pasteur/GSK  Protein Subunit SARS-CoV-2 vaccine formulation 1 with adjuvant 1  (baculovirus production) 2 0, 21  IM ‡T/‡U @ @
Biological E Ltd@(ƒCƒ“ƒhj Protein Subunit BECOV2 2 0, 28 IM ‡T/‡U@ @ @
Israel Institute for Biological Research Replicating Viral Vector rVSV-SARS-CoV-2-S Vaccine  1 @ IM ‡T/‡U @ @
Arcturus Therapeutics i•ฤj RNA ARCT-021 @ @ IM ‡U @ @
Serum Institute of India + Accelagen Pty + SpyBiotech Virus like particle RBD-HBsAg VLPs 2 0, 28 IM ‡T/‡U @ @
Symvivo Corporation ƒJƒiƒ_ DNA based bacTRL-Spike oral DNA vaccine 1 @ oral ‡T @ @
ImmunityBio, Inc & Nantkwest Inc@•ฤ Non-Replicating Viral Vector hAd5-S-Fusion+N-ETSD vaccine 1-2 @ SC or Oral ‡T@ @ @
ReiTheraiˆษj/LEUKOCAREi“ฦj/Univercellsiƒxƒ‹ƒM[j Non-Replicating Viral Vector GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) 1 @ IM ‡T @ @
Vaxart@•ฤ Non-Replicating Viral Vector VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform 2 0, 28 oral ‡T @ @
University of Munich (Ludwig-Maximilians) Non-Replicating Viral Vector MVA-SARS-2-5 2 0, 28 IM ‡T @ @
Clover Biopharmaceuticals Inc./GSK/Dynavax SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant  (Native like Trimeric subunit Spike Protein vaccine)   Native like Trimeric subunit Spike Protein vaccine 2 0, 21 IM ‡U/‡V @ @
Vaxine Pty Ltdi‹j Protein Subunit COVAX-19® Recombinant spike protein + adjuvant 1 @ IM ‡T @ @
University of Queensland/CSLi‹j/Seqirusi‰pj Protein Subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine  2 0, 28 IM ‡T @ @
Medigen Vaccine Biologicsi‘ไ˜pj/NIAID/Dynavax Protein Subunit MVC-COV1901 (S-2P protein + CpG 1018) 2 0, 28 IM ‡U @ @
Instituto Finlay de Vacunas, Cuba Protein Subunit FINLAY-FR anti-SARS-CoV-2 Vaccine (RBD + adjuvant) 2 0, 28 IM ‡U @ @
West China Hospital, Sichuan University Protein Subunit RBD (baculovirus production expressed in Sf9 cells)  Recombinant SARS-CoV-2 vaccine (Sf9 Cell)  2 0, 28 IM ‡U @ @
University Hospital Tuebingen@“ฦ Protein Subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) 1 @ SC ‡T @ @
COVAXX + United Biomedical Inc Protein Subunit UB-612 (Multitope peptide based S1-RBD-protein based vaccine) 2 0, 28 IM ‡U/‡V @ @
Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + Univeristy of Pittsburgh Replicating Viral Vector V591-001  - Measles-vector based (TMV-o38) 1-2 0
0, 28
IM ‡T/‡U @ @
Imperial College London RNA LNP-nCoVsaRNA 2 @ IM ‡T @ @
Academy of Military Science (AMS), Walvax Biotechnology i‰]“์—€Xถ•จjand Suzhou Abogen Biosciences RNA SARS-CoV-2 mRNA vaccine (ARCoV) 2 0, 14
or
0, 28
IM ‡T @ @
MedicagoiƒJƒiƒ_@“c•ำŽO•Hป–๒j VLP Coronavirus-Like Particle COVID-19 (CoVLP) 2 0, 21 IM ‡U/‡V @ @
Shenzhen Geno-Immune Medical Institute   Viral vector (Replicating) + APC Covid-19/aAPC vaccine.   The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). 3

@

0, 14, 28 SC ‡T @ @
Shenzhen Geno-Immune Medical Institute  Viral vector (Non-replicating) + APC LV-SMENP-DC vaccine.   Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. ‚P @ SC & IV ‡T/‡U @ @
Adimmune Corporation  Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) @ @ @ ‡T @ @
Entos Pharmaceuticals Inc.  DNA based Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation ‚Q

@

0, 14 IM ‡T @ @
Providence Health & Services DNA based CORVax - Spike (S) Protein Plasmid DNA Vaccine  2 0, 14 ID ‡T @ @
Chulalongkorn University RNA based ChulaCov19 mRNA vaccine 2 0, 21 IM ‡T @ @
City of Hope Medical Center + National Cancer Institute Viral vector (Non-replicating) COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 1-2 0, 28 IM ‡T @ @
Aivita Biomedical, Inc.
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19.  A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF 1 @ IM ‡T/‡U @ @
Codagenix/Serum Institute of India Live attenuated virus COVI-VAC 1
2

0,28
IN ‡T @ @
Center for Genetic Engineering and Biotechnology (CIGB)  Protein subunit CIGB-669 (RBD+AgnHB) 3 0,14,28 or
0,28,56
IM ‡T/‡U @ @
Center for Genetic Engineering and Biotechnology (CIGB)  Protein subunit CIGB-66 (RBD+aluminium hydroxide)   3 0,14,28 or
0,28,56
IM ‡T/‡U @ @
Valneva, National Institute for Health Research, United Kingdom Inactivated Virus VLA2001 2 0,21 IM ‡T/‡U @ @
Cellid Co., Ltd. Viral vector (Replicating) AdCLD-CoV19 (adenovirus vector)  1 @ IM ‡T/‡U @ @
GeneOne Life Science, Inc. DNA based vaccine GLS-5310 2 0,56 or
0,84
ID ‡T/‡U @ @
Nanogen Pharmaceutical Biotechnology Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted 2 0,21 IM ‡T/‡U @ @
Shionogi Protein subunit Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) 2 2,21 IM ‡T/‡U @ @
Altimmune, Inc. Viral vector (Non-replicating) AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein 1-2 @ IN ‡T @ @
University Medical Center Groningen + Akston Biosciences Inc. Protein subunit SARS-CoV-2-RBD-Fc fusion protein @ @ SC or IM ‡T/‡U @ @
Erciyes University Inactivated Virus ERUCOV-VAC, inactivated virus  2 0,21 IM ‡T @ @
Vaccine and Infectious Disease Organization (VIDO) +Seppic and the Vaccine Formulation Institute (VFI) Protein subunit COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant  2 0,28 IM ‡T/‡U @ @